The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

THIRUVANANTHAPURAM: Chief Minister Pinarayi Vijayan on Wednesday released a textbook on diabetes management, published by ...

Diabetes, which affects 4% of adults globally, can cause severe complications such as kidney disease and nerve damage.

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and automation, the reality is that many of us have been integrating AI into our ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...